Biotech Acquisitions Surge as VC Optimism Grows

Small M&A Deals Signal Hope for Biotech Venture Capitalists

Biotechnology venture capitalists are finding reasons to be hopeful for the future of their industry after two years of declining investment. Recent acquisitions of small drugmakers have provided a glimmer of hope for stabilization and growth within the biotech sector. These purchases, which have taken place in recent weeks, follow a busy fourth quarter of mergers and acquisitions within the industry. For venture capitalists, these M&A deals represent an opportunity for returns at a time when few biotech companies are going public.